Nationwide Case Review
Call 24/7 1-800-883-9858

  • Drugs Recalls
  • Devices and Implants
  • FDA Alerts
  • About Us
  • Español
  • Contact Us
Nationwide Case Review
Call 24/7 1-800-883-9858

  • Drugs Recalls
  • Devices and Implants
  • FDA Alerts
  • About Us
  • Español
  • Contact Us
Nationwide Case Review
Call 24/7 1-800-883-9858

  • Drugs Recalls
  • Devices and Implants
  • FDA Alerts
  • About Us
  • Español
  • Contact Us

FDA Raptiva Recall Statement

  • Home
  • FDA Reports FDA Recalls
  • FDA Raptiva Recall Statement
Published by on April 8, 2009
Categories
  • FDA Recalls
Tags

Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market. The company is taking this action because of a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML), a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system. By June 8, 2009, Raptiva will no longer be available in the United States.

Prescribers are being asked not to initiate Raptiva treatment for any new patients. Prescribers should immediately begin discussing with patients currently using Raptiva on how to transition to alternative therapies. The FDA strongly recommends that patients work with their health care professional to transition to other alternative therapies for psoriasis.

The risk that an individual patient taking Raptiva will develop PML is rare and is generally associated with long-term use. Generally, PML occurs in people whose immune systems have been severely weakened and often leads to an irreversible decline in neurologic function and death. There is no known effective treatment for PML. On Oct. 16, 2008, FDA updated the FDA-approved labeling for Raptiva to warn of the risk of life-threatening infections, including PML. On Feb. 19, 2009, the FDA issued a Public Health Advisory informing patients and prescribers of the risk of PML in patients taking Raptiva, after receiving reports of four patients with PML, three of whom died. On March 13, 2009, the FDA approved a Medication Guide for Raptiva and included additional information in Raptiva’s labeling regarding PML.

Raptiva was approved by the FDA in 2003. It is a once-weekly injection for adults with moderate to severe plaque psoriasis.

Prescribers should continue to monitor patients on Raptiva for neurologic symptoms that might represent PML.

Share

Review My Case

Free & Confidential Consultation

    board-certified-lawyer

    Attorney David P. Willis is a nationally recognized Trial Lawyer with more than 37 years of fighting for his clients' rights. Mr. Willis is a former Briefing Attorney for the Supreme Court of Texas and he is Board Certified in Personal Injury Trial Law since 1988.

    attorney-david-willis

    "Through his many years of dedication and service to his clients, David Willis has been successful in forcing many billion dollar corporations to make major safety changes to their products and the ways they conduct business."

    Willis-Law-Firm-awards
    Willis-Law-Firm-awards

    willis logo white

    Principle Office Location
    5005 Riverway Drive
    Suite 160
    Houston, TX 77056
    Call 24/7 1-800-883-9858

    THIS IS ATTORNEY ADVERTISING

    Contact Us Español About Us Notices & Disclaimer Privacy Policy

    © 2006-2020 Willis Law Firm. All Rights Reserved. Sitemap